RET and pancreatic neuroendocrine tumor: Nonetheless, late-onset manifestations of MEN1, such as asymptomatic pancreatic neuroendocrine tumors in patients over 70 years old, have been documented [3], and low-penetrance RET mutations (e.g., K666N) have been associated with delayed MEN2 diagnoses and milder phenotypes [4].